Verge Starts First-in-human Trial of Its Novel PIKfyve Inhibitor for ALS
Four years after its discovery via an artificial intelligence (AI) platform, Verge Genomics will test its amyotrophic lateral…
Articles by Marisa Wexler, MS
New Study Uncovers Mechanism of CuATSM, ALS Therapy Now in Trials
CuATSM, a potential amyotrophic lateral sclerosis (ALS) therapy that’s now in clinical trials, may work by altering how certain…
Air Pollution Exposure Tied to Greater ALS Risk in Women in Study
Higher long-term exposure to certain forms of air pollution — specifically coarse particulate matter, such as that from traffic pollutants…
Machine Learning May Help Predict ALS Progression
Deep machine-learning models using neural networks — computer algorithms inspired in the biological networks of the human brain —may help…
Earlier Start With Riluzole Could Help to Prolong Survival With ALS
Starting treatment with riluzole earlier in the disease course could prolong overall survival for people with amyotrophic lateral sclerosis…
Via Orphan Drug Grant Program, FDA Funds New ALS Research
The U.S. Food and Drug Administration (FDA) is funding several novel research projects related to amyotrophic lateral sclerosis (ALS)…
‘Good Cholesterol’ Protein Improved Blood Vessel Cell Health
A cholesterol-related protein, called apolipoprotein A1 (ApoA1), can prevent the death of endothelial cells — those lining blood vessel walls…
Trial Planned Into Digital, Home Monitoring of ALS Progression
The nonprofit EverythingALS is teaming up with several biotech companies for a study into the feasibility of monitoring amyotrophic…
3 HGF-based Therapies in the Works With Helixmith’s DART Program
Helixmith has unveiled its new multi-approach program called DART — Defeating ALS through Regenerative Therapeutics — to develop new…
Review Finds ‘No Strong Evidence’ Linking Medicines With ALS Risk
There is no compelling evidence to suggest any medication increases the risk of developing amyotrophic lateral sclerosis (ALS), according…